BioSpace News Archive

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), today announced that it will host an Investor and Analyst call and webcast on Tuesday, October 12, 2021.

BeiGene (NASDAQ: BGNE; HKEX: 06160), today announced that BRUKINSA® (zanubrutinib) has been approved in Australia for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or in first line treatment for patients unsuitable for chemo-immunotherapy.

Jane Andrews, PhD, Founder & CEO of Cell Bridge Strategies, LLC has partnered with Michelle Lott, RAC, Principal & Founder of leanRAQA, to add more depth to the regulatory affairs and quality management system expertise offered to their customers.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new promising data from a study evaluating the effects of SBT-272 in a murine model of amyotrophic lateral sclerosis (ALS).

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today issued the following statement concerning the inadvertent issuance of an abstract by the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics (“ANE Conference”).

Takeda Pharmaceutical Company Limited announced the U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee voted unanimously to recommend use of maribavir for the treatment of refractory cytomegalovirus infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Rain Therapeutics Inc.,, a late-stage company developing precision oncology therapeutics, announced data on its oral mouse double minute 2 inhibitor, milademetan, presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics held virtually October 7-10, 2021.

Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”) announced today that the Company has reached agreement with Mid-Atlantic BioTherapeutics (MABT) to broaden its previously announced license of IMT504, a novel patented immunotherapy and adjuvant, to include the development of a next generation COVID-19 vaccine.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced that Hans van der Vliet, M.D,. Ph.D., chief scientific officer at LAVA, will present at the AACR-NCI-EORTC Virtual International Conference.

Cerner Corporation, a global healthcare technology company, will host its annual Cerner Health Conference, next week, Oct. 12-13, kicking off with Dr. David Feinberg, Cerner’s new president and CEO.